Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of GAD-alum immunotherapy associated with HLA-DR3-DQ2 in recently diagnosed type 1 diabetes

4 Aug 2020

Abstract excerpt

AIMS/HYPOTHESIS: The aim of this study was to determine if retention of C-peptide following immunotherapy using recombinant GAD65 conjugated to aluminium hydroxide (GAD-alum) is influenced by HLA risk haplotypes DR3-DQ2 and DR4-DQ8. METHODS: HLA-dependent treatment effect of GAD-alum therapy on C-peptide retention in individuals with recent-onset type 1 diabetes was evaluated using individual-level patient data...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Diabetes and associated disorders
Share to Pancreatic function and diabetes
Share to T-cell and B-cell Immunology

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32754804
DOI: 10.1007/s00125-020-05227-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 15 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of GAD-alum immunotherapy associated with HLA-DR3-DQ2 in recently diagnosed type 1 diabetesPMID 32754804Read ↗

Efficacy and Safety of GAD- alum Immunotherapy in recent onset Type-1 diabetes: A systematic review and meta-analysisSemantic proximity Read ↗

Decreased GAD(65)-specific Th1/Tc1 phenotype in children with Type 1 diabetes treated with GAD-alum.Semantic proximity Read ↗

Characteristics of in-vitro phenotypes of glutamic acid decarboxylase 65 autoantibodies in high-titre individuals.Semantic proximity Read ↗

Soluble antigen arrays improve the efficacy and safety of peptide-based tolerogenic immunotherapySemantic proximity Read ↗

Detection of Antibodies Directed to the N-Terminal Region of GAD Is Dependent on Assay Format and Contributes to Differences in the Specificity of GAD Autoantibody Assays for Type 1 DiabetesSemantic proximity Read ↗

Naturally processed T cell epitopes from human glutamic acid decarboxylase identified using mice transgenic for the type 1 diabetes-associated human MHC class II allele, DRB1*0401.Semantic proximity Read ↗

Autoantibodies to N-terminally truncated GAD improve clinical phenotyping of individuals with adult-onset diabetes: Action LADA 12.Semantic proximity Read ↗

Dynamic changes of GAD65 autoantibody epitope specificities in individuals at risk of developing type 1 diabetes.Semantic proximity Read ↗

Association of Serum Anti-GAD Antibody and HLA Haplotypes with Type 1 Diabetes Mellitus Triggered by Nivolumab in Patients with Non–Small Cell Lung CancerSemantic proximity Read ↗

Major DQ8-restricted T-cell epitopes for human GAD65 mapped using human CD4, DQA1*0301, DQB1*0302 transgenic IA(null) NOD mice.Semantic proximity Read ↗

Single domain antibody-antigen adducts that target Class II MHC induce antigen-specific toleranceSemantic proximity Read ↗

Identification of immunodominant T cell epitopes of human glutamic acid decarboxylase 65 by using HLA-DR(alpha1*0101,beta1*0401) transgenic mice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.